Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Robert M.A. Thwaites"'
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 24(9)
The value of real-world evidence (RWE) in medicines regulation and health technology assessment has been increasingly emphasized. Nevertheless, although RWE is increasingly used, there has been limited systematic evidence of its value. A recent study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28ad3805a65813689800b8a49e2090ee
https://pubmed.ncbi.nlm.nih.gov/34452702
https://pubmed.ncbi.nlm.nih.gov/34452702
Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma
Publikováno v:
Clinical Therapeutics. 22:1562-1574
Background: The results of a recent meta-analysis comparing 2 inhaled corticosteroids, fluticasone propionate (FP) and budesonide, demonstrated that FP had an improved efficacy-to-safety ratio compared with budesonide. However, limited data are avail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51e083cfed021c9a872d9b89967a398f
https://doi.org/10.1016/s0149-2918(00)83054-4
https://doi.org/10.1016/s0149-2918(00)83054-4
Autor:
Gunnar Johansson, Seema Sondhi, Robert M.A. Thwaites, Bo Lundbäck, Willem R. Pieters, Martin J. Price, Mona Palmqvist
Publikováno v:
PharmacoEconomics. 16:1-8
When a new drug therapy is introduced, it is important to consider the economic impact of the treatment. This is particularly relevant for a chronic disease such as asthma. Despite an increased understanding of the physiology of asthma, this conditio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::988eb0fc59c15c8b0b98f58755d1a488
https://doi.org/10.2165/00019053-199916002-00001
https://doi.org/10.2165/00019053-199916002-00001
Publikováno v:
PharmacoEconomics. 16:29-34
Methods: An economic analysis was performed to compare the cost effectiveness of a new formulation combining salmeterol 50μg and fluticasone propionate 500μg in a multidose dry powder (Diskus™) inhaler (n = 167) with that of fluticasone propionat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad3b7137807578b534f922e53367a708
https://doi.org/10.2165/00019053-199916002-00005
https://doi.org/10.2165/00019053-199916002-00005
Autor:
Martin J. Price, Willem R. Pieters, Mona Palmqvist, Bo Lundbäck, Gunnar Johansson, Songkai Yan, Seema Sondhi, Robert M.A. Thwaites
Publikováno v:
PharmacoEconomics. 16:9-14
Asthma is a common chronic disease that places a large financial burden on healthcare systems and society. It is therefore important to consider the economic impact of new asthma therapies. Three economic analyses were performed using clinical data f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d0689b2bcb8ff6eded9300173b57014
https://doi.org/10.2165/00019053-199916002-00002
https://doi.org/10.2165/00019053-199916002-00002